Since we have demonstrated that MG53 exerted the anti-tumor effect by inhibiting RAC1-MAPK pathway, thus we further try to clarify whether MG53 could play a role in the response to sorafenib treatment in HCC. This evidence concerns the gene RAC1 and hepatocellular carcinoma.